Xoma
XOMA Corporation is a biotechnology company focused on the discovery and development of therapeutic candidates, primarily in the fields of monoclonal antibodies and innovative drug technologies. With a robust pipeline, the company is developing proprietary product candidates such as X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody for Type 2 diabetes; and therapies targeting metastatic melanoma and renal cell carcinoma. XOMA also has initiatives aimed at addressing unmet medical needs related to hyperparathyroidism. In addition to its own product development, the company licenses antibody discovery and optimization technologies and collaborates with major pharmaceutical firms, including Novartis and Takeda, to enhance clinical development efforts. Founded in 1981 and headquartered in Emeryville, California, XOMA is positioned at the forefront of biopharmaceutical innovation, contributing to advancements in healthcare.
Pulmokine
Acquisition in 2024
Pulmokine is a privately held biopharmaceutical company dedicated to developing therapies for challenging pulmonary diseases, specifically focusing on conditions such as pulmonary arterial hypertension (PAH), pulmonary arterial fibrosis, interstitial lung disease, sarcoidosis, and lung cancer. Leveraging innovative kinase inhibitor technology, Pulmokine aims to create effective treatments that address the needs of patients suffering from these serious lung conditions. Through its targeted approach, the company seeks to improve patient outcomes and expand the options available for managing difficult-to-treat pulmonary ailments.
Dare Bioscience
Post in 2024
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.
Kinnate Biopharma
Acquisition in 2024
Kinnate Biopharma Inc. is a biopharmaceutical company based in San Diego, California, focused on developing small molecule kinase inhibitors for the treatment of genomically defined cancers. Founded in 2018, the company aims to create precision oncology therapeutics to address the needs of underserved patient populations. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is working on KIN003, which targets specific alterations in the FGFR2 and FGFR3 genes, and has other small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor. Kinnate Biopharma employs expertise in structure-based drug discovery and translational research to advance its pipeline of candidates aimed at treating cancers associated with specific oncogenic alterations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.